Takeda Oncology
Kimberly Phillips serves as the Associate Director and Clinical Operations Program Lead at Takeda Oncology since December 2020, providing operational expertise and strategic input for oncology clinical programs. Prior to this role, Kimberly was the Clinical Operations Associate Director at Celyad Oncology SA, where responsibilities included overseeing multiple CAR T clinical programs and ensuring compliance with quality standards. Kimberly's experience at Pfizer as a Clinical Project Manager included managing operational oversight for Phase I oncology trials, while earlier roles at Dana-Farber Cancer Institute involved managing a comprehensive range of clinical trials. Kimberly began a career in clinical research as a Clinical Research Coordinator at Dana-Farber after serving as a Research Assistant at the University of Rochester, where a Bachelor of Arts in Brain and Cognitive Studies was earned.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.